|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pyrrolidine dithiocarbamate reduces ischemia-reperfusion injury of the small intestine显示文摘AIM: To evaluate whether pyrrolidine dithiocarbamate (PDTC), an enhancer of HO production, attenuates intestinal IR injury.METHODS: Eighteen male rats were randomly allocated into three groups: (a) sham; (b) IR, consisting of 30 min of intestinal ischemia, followed by 2-h period of reperfusion; and (c) PDTC treatment before IR. Intestinal microvascular perfusion (IMP) was monitored continuously by laser Doppler fiowmetry. At the end of the reperfusion, serum samples for lactate dehydrogenase (LDH) levels and biopsies of ileum were obtained. HO activity in the ileum was assessed at the end of the reperfusion period.RESULTS: At the end of the reperfusion in the IR group,IMP recovered partially to 42.5% of baseline (P<0.05vs sham), whereas PDTC improved IMP to 67.3% of baseline (P<0.01 vs IR). There was a twofold increase in HO activity in PDTC group (2 062.66±106.11) as compared to IR (842.3±85.12) (P<0.001). LDH was significantly reduced (P<0.001) in PDTC group (585.6±102.4)as compared to IR group (1 973.8±306.5). Histological examination showed that the ileal mucosa was significantly less injured in PDTC group as compared with IR group.CONCLUSION: Our study demonstrates that PDTC improves the IMP and attenuates IR injury of the intestine possibly via HO production. Additional studies are warranted to evaluate the clinical efficacy of PDTC in the prevention of IR injury of the small intestine. | Ismail H Mallick Wen-Xuan Yang Marc C Winslet Alexander M Seifalian | 2005 | World Journal of Gastroenterology2005，11，46： | 8 |
| 2 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 3 | Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma显示文摘Glioblastoma multiforme(GBM) is the most common malignant primary brain tumor with a survival prognosis of 14-16 mo for the highest functioning patients. Despite aggressive, multimodal upfront therapies, the majority of GBMs will recur in approximately six months. Salvage therapy options for recurrent GBM(r GBM) are an area of intense research. This study compares recent survival and quality of life outcomes following Gamma Knife radiosurgery(GKRS) salvage therapy. Following a Pub Med search for studies usingGKRS as salvage therapy for malignant gliomas, nine articles from 2005 to July 2013 were identified which evaluated rG BM treatment. In this review, we compare overall survival following diagnosis, overall survival following salvage treatment, progression-free survival, time to recurrence, local tumor control, and adverse radiation effects. This report discusses results for rG BM patient populations alone, not for mixed populations with other tumor histology grades. All nine studies reported median overall survival rates(from diagnosis, range:16.7-33.2 mo; from salvage, range:9-17.9 mo). Three studies identified median progression-free survival(range:4.6-14.9 mo). Two showed median time to recurrence of GBM. Two discussed local tumor control. Six studies reported adverse radiation effects(range:0%-46% of patients). The greatest survival advantages were seen in patients who received GKRS salvage along with other treatments, like resection or bevacizumab, suggesting that appropriately tailored multimodal therapy should be considered with each rG BM patient. However, there needs to be a randomized clinical trial to test GKRS for rG BM before the possibility of selection bias can be dismissed. | Erik W Larson Halloran E Peterson Wayne T Lamoreaux Alexander R MacKay Robert K Fairbanks Jason A Call Jonathan D Carlson Benjamin C Ling John J Demakas Barton S Cooke Christopher M Lee | 2014 | World Journal of Clinical Oncology2014，5，2： | 5 |
| 4 | Label-retaining liver cancer cells are relatively resistant to sorafenib显示文摘 | Hong-Wu Xin Chenwi M Ambe Danielle M Hari Gordon W Wiegand Tyler C Miller Jin-Qiu Chen Andrew J Anderson Satyajit Ray John E Mullinax Tomotake Koizumi Russell C Langan Douglas Burka Michelle A Herrmann Paul K Goldsmith Alexander Stojadinovic Udo Rudloff S | 2013 | Gut2013，，12： | 2 |
| 5 | A Comparison of Message Passing and Shared Memory Architectures for Data Parallel Programs显示文摘 | Alexander C K Hery M L | 1994 | ACM SIGARCH Computer Architecture News1994，22，2： | 1 |
| 6 | Cerebral isehemia and inflammation 显示文摘 | Iadecola C Alexander M | 2001 | Curr Opin Neurol2001，14，： | 1 |
| 7 | Distribution of P, K, Ca, Mg, B, Cu, Mn and Zn in peanut lines near maturity 显示文摘 | Hallock D L Martens D C Alexander M W | 1971 | Agronomy Journal1971，63，2： | 1 |
| 8 | MAP kinase pathways in the yeast Soccharomyces cerevisiae显示文摘 | Gustin M C Albertyn J Alexander M et 01 | 1998 | Microbiol Mol Biol Rev1998，62，8： | 1 |
| 9 | Membranous glomerulonephritis is a manifestation of IgG4-related disease 显示文摘 | Alexander M P Larsen C P Gibson I W | 2013 | Kidney international2013，83，3： | 1 |
| 10 | Characterization of ureaso activity in three marine phytoplankton species,Aureococcus anophagefferens,Prorocentrum minimum,and Thalassiosira weissflogii显示文摘 | FAN C GLIBERT P M ALEXANDER J | 2003 | Marine Biology2003，142，： | 1 |
| 11 | Sexual arousal and organs in women:effect of spinal cord injury显示文摘 | Sipski M L Alexander C J Rosen R | 2001 | Ann Neurol2001，49，1： | 1 |
| 12 | The relationship of the serum potassium to the pletelets count in children 显示文摘 | William L M Amin M K Alexander K C | 1992 | Clin Pediat1992，31，2： | 1 |
| 13 | Induction of synde-can -1 expression in stromal fibroblasts promotes proliferation of hu-man breast cancer cells显示文摘 | MAEDA T ALEXANDER C M FHIEDL A | 2004 | Cancer Res2004，64，2： | 1 |
| 14 | Design and internal validation of an obstetric early warning score : secondary analysis of the Intensive Care National Audit and Research Centre Case Mix Programme database显示文摘 | Carle C Alexander P Columb M | 2013 | Anaesthesia2013，68，4： | 1 |
| 15 | An infrared spectroscopy study of the hydrogen bonding and water restructuring as a trisiloxane superspreading surfactant adsorbs onto an aqueous hydrophobic surface 显示文摘 | NITIN K CHARL E M ALEXANDER C | 2006 | Colloids Surf A2006，210，： | 1 |
| 16 | Metalloproteinase mediate extracellular matrix degradation by ceils from mouse blastocyst outgrowths显示文摘 | Behrendtsen O Alexander C M Werb Z | 1992 | Development1992，114，2： | 1 |
| 17 | Manufacturing Technology 显示文摘 | Alexander J M Brewer R C Rowe G W | 1999 | Tribology Transactions1999，59，2： | 1 |
| 18 | Vector Fidelity of Land Multicomponent Measurements in the Context of the Earth-Sensor System:Misconceptions and Implications显示文摘 | Donald N B Alexander S C John M N GX Technology | 2005 | SEG/Houston 2005 Annual Meeting2005，，： | 1 |
| 19 | Cerebral ischemia and inflam- mation显示文摘 | Iadecola C Alexander M | 2001 | Curr Opin Neurol2001，14，1： | 1 |
| 20 | Reacttions in supererifical fluid: a case study of the thermo-dynamie solvent effects on a Diels-Alder reaction in supercritical CO2显示文摘 | Paulaitis M E Alexander G C | 1987 | Pure and Applied Chemistry1987，59，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员